e-Bio is a clinical-stage medical device company developing an electrically stimulating device designed to diminish or stop uterine contractions in preterm pregnancies. Its proprietary electric-inhibition technology has progressed from animal studies to FDA-authorized human clinical trials, with the first phase supported by a March of Dimes grant. The company is led by CEO Denis Schapira Wajman, Chief Medical Officer Frederick Naftolin, and Chief Scientific Officer Jeffrey Karsdon.
FDA Investigational Device Exemption (IDE)
Compliance program
FDAIDE
Quality certification